Larimar Therapeutics (LRMR) Earnings Date & Reports
A.I. Advisor
published Earnings
LRMR is expected to report earnings to rise 10.91% to -37 cents per share on November 12
Q3'24
Est.
$-0.38
Q2'24
Missed
by $0.03
Q1'24
Missed
by $0.03
Q4'23
Missed
by $0.05
Q3'23
Beat
by $0.01
The last earnings report on August 07 showed earnings per share of -34 cents, missing the estimate of -30 cents. With 788.44K shares outstanding, the current market capitalization sits at 567.88M.
a clinical-stage biopharmaceutical company, which engages in the research and development of a therapeutic treatment for mitochondrial disorders and Friedreich's ataxia